Related Experiment Video
Updated: Mar 26, 2026

Inducible and Reversible Dominant-negative DN Protein Inhibition
Published on: January 7, 2019
Tumor suppressor properties of the splicing regulatory factor RBM10
Jordi Hernández1,2, Elias Bechara1,2, Doerte Schlesinger1
1a Centre de Regulació Genòmica, The Barcelona Institute of Science and Technology , Dr. Aiguader 88, 08003 Barcelona , Spain.
Abstract:
RBM10 is an RNA binding protein and alternative splicing regulator frequently mutated in lung adenocarcinomas. Recent results indicate that RBM10 inhibits proliferation of lung cancer cells by promoting skipping of exon 9 of the gene NUMB, a frequent alternative splicing change in lung cancer generating a negative regulator of Notch signaling. Complementing these observations, we show that knock down of RBM10 in human cancer cells enhances growth of mouse tumor xenografts, confirming that RBM10 acts as a tumor suppressor, while knock down of an oncogenic mutant version of RBM10 reduces xenograft tumor growth. A RBM10 mutation found in lung cancer cells, V354E, disrupts RBM10-mediated regulation of NUMB alternative splicing, inducing the cell proliferation-promoting isoform. We now show that 2 natural RBM10 isoforms that differ by the presence or absence of V354 in the second RNA Recognition Motif (RRM2), display similar regulatory effects on NUMB alternative splicing, suggesting that V354E actively disrupts RBM10 activity. Structural modeling localizes V354 in the outside surface of one α-helix opposite to the RNA binding surface of RBM10, and we show that the mutation does not compromise binding of the RRM2 domain to NUMB RNA regulatory sequences. We further show that other RBM10 mutations found in lung adenocarcinomas also compromise regulation of NUMB exon 9. Collectively, our previous and current results reveal that RBM10 is a tumor suppressor that represses Notch signaling and cell proliferation through the regulation of NUMB alternative splicing.
Insights
RNA binding protein 10 (RBM10) acts as a tumor suppressor in lung adenocarcinomas by regulating NUMB alternative splicing and repressing Notch signaling. Mutations disrupt this function, promoting cancer cell proliferation.
Area of Science:
- Molecular Biology
- Cancer Research
- RNA Splicing
Background:
- RBM10 (RNA binding protein 10) is frequently mutated in lung adenocarcinomas.
- RBM10 regulates NUMB alternative splicing, impacting Notch signaling and cell proliferation.
- RBM10 functions as a tumor suppressor in lung cancer.
Purpose of the Study:
- To investigate the role of RBM10 mutations in lung adenocarcinoma.
- To elucidate the mechanism by which RBM10 regulates NUMB alternative splicing.
- To confirm the tumor suppressor activity of RBM10.
Main Methods:
- Xenograft tumor growth assays in mice.
- Analysis of RBM10 isoforms and mutations.
- Structural modeling of RBM10.
- RNA binding studies.
Main Results:
- RBM10 knockdown enhances tumor growth; knockdown of oncogenic RBM10 mutants reduces growth.
- The V354E mutation disrupts RBM10's regulation of NUMB exon 9 splicing.
- V354E mutation does not affect RBM10's RNA binding affinity.
- Other lung cancer-associated RBM10 mutations also impair NUMB exon 9 regulation.
Conclusions:
- RBM10 is a tumor suppressor that inhibits Notch signaling and cell proliferation.
- RBM10's tumor suppressor function is mediated through NUMB alternative splicing regulation.
- Specific RBM10 mutations found in lung adenocarcinomas compromise its tumor-suppressive activity by disrupting NUMB splicing regulation.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation
RNA Splicing
RNA Splicing
Negative Regulator Molecules
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...

